The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Open accessAbstract
BACKGROUND: Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylaxis in persons who have hemophilia A without factor VIII inhibitors. METHODS: We randomly assigned, in a 2:2:1 ratio, participants 12 years of age or older who had been receiving episodic treatment with factor VIII to receive a subcutaneous maintenance dose of emicizumab of 1.5 mg per kilogram of body weight per week (group A) or 3.0 mg per kilogram every 2 weeks (group B) or no prophylaxis (group C). The primary end point was the difference in rates of treated bleeding (group A vs. group C and group B vs. group C). Participants who had been receiving factor VIII prophylaxis received emicizumab at a maintenance dose of 1.5 mg per kilogram per week (group D); intraindividual comparisons were performed in those who had participated in a noninterventional study. RESULTS: A total of 152 participants were enrolled. The annualized bleeding rate was 1.5 events (95% confidence interval [CI], 0.9 to 2.5) in group A and 1.3 events (95% CI, 0.8 to 2.3) in group B, as compared with 38.2 events (95% CI, 22.9 to 63.8) in group C; thus, the rate was 96% lower in group A and 97% lower in group B (P<0.001 for both comparisons). A total of 56% of the participants in group A and 60% of those in group B had no treated bleeding events, as compared with those in group C, who all had treated bleeding events. In the intraindividual comparison involving 48 participants, emicizumab prophylaxis resulted in an annualized bleeding rate that was 68% lower than the rate with previous factor VIII prophylaxis (P<0.001). The most frequent adverse event was low-grade injection-site reaction. There were no thrombotic or thrombotic microangiopathy events, development of antidrug antibodies, or new development of factor VIII inhibitors. CONCLUSIONS: Emicizumab prophylaxis administered subcutaneously once weekly or every 2 weeks led to a significantly lower bleeding rate than no prophylaxis among persons with hemophilia A without inhibitors; more than half the participants who received prophylaxis had no treated bleeding events. In an intraindividual comparison, emicizumab therapy led to a significantly lower bleeding rate than previous factor VIII prophylaxis. (Funded by F. Hoffmann-La Roche and Chugai Pharmaceutical; HAVEN 3 ClinicalTrials.gov number, NCT02847637 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703068 · Cited by 1,121
Self-citationThe hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 507
Self-citationFactor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., & Nogami, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511769 · Cited by 478
Self-citationSampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Thinking about the burden of treatment
Mair, F. S., & May, C. R. (2014) · BMJ · doi:10.1136/bmj.g6680 · Cited by 293
Kitazawa, T., Esaki, K., Tachibana, T., Ishii, S., Soeda, T., Muto, A., Kawabe, Y., Igawa, T., Tsunoda, H., Nogami, K., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-01-0030 · Cited by 207
Self-citationHemophilia A in the third millennium
Franchini, M., & Mannucci, P. M. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.002 · Cited by 167
A systematic review of patient-reported measures of burden of treatment in three chronic diseases
Eton, D. T., Elraiyah, T. A., Yost, K. J., Ridgeway, J. L., Johnson, A., Egginton, J. S., Mullan, R. J., Murad, M. H., Erwin, P. J., & Montori, V. M. (2013) · Patient Related Outcome Measures · doi:10.2147/prom.s44694 · Cited by 146
Khawaji, M., Astermark, J., & Berntorp, E. E. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01750.x · Cited by 95
Yoneyama, K., Schmitt, C., Kotani, N., Levy, G. G., Kasai, R., Iida, S., Shima, M., & Kawanishi, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0616-3 · Cited by 85
Self-citationFuture of coagulation factor replacement therapy
Peyvandi, F., Garagiola, I., & Seregni, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12270 · Cited by 76
Miller, C. H., Rice, A. S., Boylan, B., Shapiro, A. D., Lentz, S. R., Wicklund, B. M., Kelly, F. M., & Soucie, J. M. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12259 · Cited by 64
The current status of prophylactic replacement therapy in children and adults with haemophilia
Ljung, R. C. R., & Andersson, N. G. (2015) · British Journal of Haematology · doi:10.1111/bjh.13365 · Cited by 60
Interpreting important health‐related quality of life change using the Haem‐A‐QoL
Wyrwich, K. W., Krishnan, S., Poon, J. L., Auguste, P., von Maltzahn, R., Yu, R., & Mackensen, S. V. (2015) · Haemophilia · doi:10.1111/hae.12642 · Cited by 50
Kingdon, H. S., & Lundblad, R. L. (2002) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20010082 · Cited by 28
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Ozelo, M. C., Mahlangu, J., Pasi, K. J., Giermasz, A., Leavitt, A. D., Laffan, M., Symington, E., Quon, D. V., Wang, J.-D., Peerlinck, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113708 · Cited by 417
Self-citationYoung, G., Liesner, R., Chang, T., Sidonio, R., Oldenburg, J., Jiménez-Yuste, V., Mahlangu, J., Kruse-Jarres, R., Wang, M., Uguen, M., et al. (2019) · Blood · doi:10.1182/blood.2019001869 · Cited by 402
Self-citationPipe, S. W., Shima, M., Lehle, M., Shapiro, A., Chebon, S., Fukutake, K., Key, N. S., Portron, A., Schmitt, C., Podolak-Dawidziak, M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30054-7 · Cited by 391
Self-citationTherapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Metadata
- Authors
- Mahlangu, J., Oldenburg, J., Paz-Priel, I., Negrier, C., Niggli, M., Mancuso, M. E., Schmitt, C., Jiménez-Yuste, V., Kempton, C., Dhalluin, C., Callaghan, M. U., Bujan, W., Shima, M., Adamkewicz, J. I., Asikanius, E., Levy, G. G., & Kruse-Jarres, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-30
- Volume
- 379
- Issue
- 9
- Pages
- 811-822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2888898681
- Cited by
- 763
- References
- 21
- FWCI
- 44.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.